LAG-3-associated CD8⁺ T-cell dysfunction in the cervical cancer tumor microenvironment

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Cytotoxic T lymphocytes (CTLs), primarily CD8+ T cells, are crucial for anti-tumor immunity within the tumor microenvironment (TME).
• Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor implicated in T cell exhaustion.
• Understanding LAG-3's role in cervical cancer is vital for developing effective immunotherapies.

Purpose of the Study:

• To investigate the expression patterns of LAG-3 in the cervical cancer TME.
• To elucidate the regulatory role of LAG-3 in CD8+ T cell function within the TME.
• To assess the correlation between LAG-3 expression and clinical parameters of cervical cancer.

Main Methods:

• Analysis of cervical tissue samples (cancer, high-grade squamous intraepithelial lesion, non-cancerous) using immunohistochemistry, Western blotting, qPCR, and fluorescence imaging.
• Establishment of a cell co-culture system and a cervical cancer mouse model.
• Evaluation of LAG-3 expression and its impact on CD8+ T cell function (cytokine production, differentiation) and tumor growth.

Main Results:

• LAG-3 expression is significantly elevated in cervical cancer TME, increasing with tumor stage, decreasing differentiation, and correlating with lymph node metastasis and lymphovascular space invasion.
• LAG-3 expression inhibits CD8+ T cell effector functions, including the production of Ki67, T-bet, TNF-α, IFN-γ, and IL-2.
• LAG-3 suppresses the differentiation of naive CD8+ T cells into central memory (TCM) and effector memory (TEM) cells, impairing anti-tumor responses.

Conclusions:

• LAG-3 is highly expressed in cervical cancer and is a significant biomarker for disease progression.
• LAG-3 negatively regulates CD8+ T cell function in the cervical cancer TME, contributing to tumor immune evasion.
• Targeting LAG-3 may represent a promising strategy to enhance anti-tumor immunity in cervical cancer.